Interview: Jürgen Pohle – CEO (as from January 2018), Neovii…
Jürgen Pohle provides both a fascinating and open account of the latest movements of Neovii; a company that possesses the ability to make decisions at the speed of a startup…
Understanding the mechanisms of disease
The Friedrich Miescher Institute is devoted to fundamental biomedical research aimed at understanding the basic molecular mechanisms of health and disease. We communicate and patent our findings to enable their translation into medical application.
The FMI focuses on the fields of
» Epigenetics
» Quantitative Biology
» Neurobiology
In these fields, the FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists
The Friedrich Miescher Institute contributes to the training of graduate students and postdoctoral fellows. Through its PhD program, which was established as early as 1970, the FMI attracts top international students. The FMI is affiliated with the University of Basel, where most of the graduate students are enrolled and where it contributes to the teaching program. Many FMI alumni have gone on to pursue successful careers in Novartis, in other pharmaceutical companies, or in academic research.
Contact
Friedrich Miescher Institute for Biomedical Research
Maulbeerstrasse 66
4058 Basel
Switzerland
Tel.: +41 61 697 66 51
Jürgen Pohle provides both a fascinating and open account of the latest movements of Neovii; a company that possesses the ability to make decisions at the speed of a startup…
Darren Kerr, CEO of Swiss medtech Stratpharma discusses, the company’s roots, its broad portfolio in dermatology, plastic surgery and scar management, as well as its growing international footprint. We…
Benjamin Rousselot of Swiss ear hygiene specialists Laboratoires Diepharmex discusses the history of the company, new products, and the pros and cons of ‘Swissness’. Laboratoires Diepharmex is a Swiss-based, family…
Benjamin Rousselot of Swiss ear hygiene specialists Laboratoires Diepharmex discusses the history of the company, new products, and the pros and cons of ‘Swissness’. Laboratoires Diepharmex is a Swiss-based, family…
Jean-François Gouzer, CEO of Scientis Pharma, discusses the company’s origin story, its specialization in skin pigmentation disorders, and future internationalization prospects Could you start by introducing the Scientis Pharma story…
Jeff Dufour, country manager Switzerland and BU lead Internal Medicine at Pfizer, discusses his first impressions of the country, his priorities for greater dialogue with Swiss healthcare insurers, and Switzerland’s…
Petra Doerr, head of sector communication & networking as well as deputy executive director of Swissmedic, the Swiss surveillance authority for medicines and medical devices, discusses changes to the Swiss regulatory system…
Ryad Dahmani, CEO of Swiss-headquartered cold chain logistics specialists, Cold Chain Vision, discusses the impact of new technology in the logistics industry, the importance of quality controls in the transportation…
Stefan Frefel, CEO of Bilfinger Industrial Services in Switzerland, outlines Bilfinger’s core offering of maintenance and engineering services to the pharmaceutical industry, the importance of the Swiss affiliate to the…
Jonathan Koch, group president R&D Laboratories at Swiss-based CRO, Covance, explains how the integration process with LabCorb has progressed over the last two years, Covance’s embrace of digitally disruptive technologies,…
Marc Funk, COO of Swiss-headquartered product development service specialist, Lonza, discusses the company’s remarkable recent fortunes, how it is implementing innovative efficiency improvements, and answers the question, “why Switzerland?” …
In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new…
See our Cookie Privacy Policy Here
